The research and practice of Judy C. Boughey, M.D., is in the field of clinical and translational research in breast cancer. Areas of specific interest include neoadjuvant chemotherapy, sentinel lymph node surgery, prophylactic mastectomy and regional anesthesia for breast surgery.
- Minimizing axillary surgery for women with node-positive breast cancer. A notable area of Dr. Boughey's focus is in the role of sentinel lymph node surgery in women with node-positive breast cancer who are treated with neoadjuvant chemotherapy. These women are usually treated with axillary lymph node dissection after chemotherapy. Dr. Boughey recently led a multicenter national study (ACOSOG-Z1071) involving 756 women across 136 institutions to evaluate the use of sentinel lymph node surgery. A successor trial (Alliance A11202) will compare axillary radiation to axillary surgery for women with residual node-positive disease after chemotherapy.
- Breast Cancer Genome-Guided Therapy (BEAUTY) study. The goal of this study is to identify novel genetic alterations and changes in cancer pathways both at the time of diagnosis and after completion of neoadjuvant chemotherapy in women with high-risk breast cancer. Both the host and tumor genomes are sequenced prior to therapy, after 12 weeks of paclitaxel and at the time of surgery. Dr. Boughey and Matthew P. Goetz, M.D., co-lead this study, which is funded by the Mayo Clinic Center for Individualized Medicine and the Mayo Clinic Cancer Center.
Significance to patient care
The results of the ACOSOG-Z1071 study are likely to change the management of women with breast cancer. Women with node-positive disease who are treated with chemotherapy prior to surgery may now be considered for sentinel lymph node surgery and potentially avoid the morbidity associated with axillary lymph node dissection.
A critical element of the BEAUTY study is the development of patient-derived xenografts in which patients' tumor tissue is kept alive by implanting tumor cells into immune-compromised mice before and after chemotherapy. The use of these mouse "avatars" allows Dr. Boughey and her colleagues to quickly determine whether the genetic alterations identified by sequencing are functional, with the initial focus on studying novel drugs and drug combinations for use in women with chemotherapy resistance.
- Vice chair, Education Committee, American College of Surgeons Clinical Research Program (ACS CRP)
See my publications
- Professor of Surgery
- Fellow - Breast Surgical Oncology University of Texas M.D. Anderson Cancer Center
- Resident Department of Surgery, Palmetto Health Richland Memorial Hospital, University of South Carolina
- Senior House Officer - Accident and Emergency Whittington Hospital, London, United Kingdom
- MA - Physiology University of Cambridge
- House Officer - General Medicine West Suffolk Hospital, Bury St. Edmunds, United Kingdom
- House Officer - General Surgery Norfolk and Norwich Hospital, United Kingdom
- MB, B Chir Addenbrooke's Hospital, University of Cambridge Clinical School
- BA - Physiology University of Cambridge